BetaGlue has closed a 10 million euro equity financing round

Theraised capitalwill give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, thus opening a new chapter in the fight against cancer

BetaGlue Technologieshasclosed a EUR 10 million equity financing round:Fin Posillipo(Petrone Group),Kairos Partners SGR,LIFTT(Venture Capital led by Stefano Buono, founder of AAA),Neva Sgr(Intesa Sanpaolo Group),ProfequycapitalandRomedwill be joining the company’s capital , with a reinvestment from existing investorsInnogest CapitalandPanakès Partners.

Theinvestment will finance BetaGlue Technologies’ future operations,aimed at reaching several milestones in Europe and the US for thedevelopment and approval of BAT-90, the company’s advanced radiotherapy platform. Key priorities in this development will be the completion of the clinical development programs that are already underway in liver and breast cancer and their regulatory approval, as well as thecompletion of the industrial scale-up in Europe and the US of the safe-biopsy device, which has already been clinically tested in lung and liver biopsy.

Riccardo Palmisano, Executive Chairman and Antonino Amato, CEO/CMO of BetaGlue Technologies, commented: “We warmly welcome our new qualified partners, who are enabling us to accelerate BetaGlue’s development plans. Together, we will be able to strengthen the cornerstones of value creation for the Company, such as the clinical development and industrial scale-up of our innovative products. This way, we are confident we will be able to deliver the precision medicine concept in radiotherapy for the benefit of patients and healthcare professionals, while strengthening the value for investors who have placed their trust in us and our technology.”